{"anticipatedPostingDate":"2026-10","denomUnitsSelected":"Participants","reportingStatus":"NOT_POSTED","timeFrame":"Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)","title":"Number of Participants With Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab) Against Elranatamab: Parts 1 and 2","type":"SECONDARY"}